← Back to Search

Innovations in Dementia Empowerment and Action (IDEA) for Alzheimer's Disease (IDEA Trial)

N/A
Waitlist Available
Led By Karen Fredriksen-Goldsen, PhD
Research Sponsored by University of Washington
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 6 weeks, 13 weeks, 30 weeks, 13 months
Awards & highlights

IDEA Trial Summary

This trial will test a disability-reducing intervention for Alzheimer's Disease among lesbian, gay, bisexual, and transgender care receiver-caregiver dyads, to manage behavioral symptoms and increase physical activity and functioning, with the goal of delaying institutionalization and improving quality of life.

Eligible Conditions
  • Alzheimer's Disease
  • Dementia
  • Mild Cognitive Impairment
  • Vascular Dementia
  • Parkinson's Disease

IDEA Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 6 weeks, 13 weeks, 30 weeks, 13 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 6 weeks, 13 weeks, 30 weeks, 13 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Perceived Stress (PSS) of Caregiver
Change in Physical Activity of Care Recipient
Change in Physical Activity of Caregiver
+2 more
Secondary outcome measures
Change in Depressive Symptomatology of Caregiver
Change in Quality of Life (QOL-AD) of Care Recipient
Change in Rate of Care-Recipient Behavioral Disturbances

IDEA Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Personalized interventionExperimental Treatment1 Intervention
Innovations in Dementia Empowerment and Action (IDEA): 9 60-minute virtual sessions for 6 weeks and 4 15-minute follow-up phone sessions for 4 months
Group II: Standard interventionActive Control1 Intervention
Reducing Disabilities in Alzheimer's Disease (RDAD): 9 60-minute virtual sessions for 6 weeks and 4 15-minute follow-up phone sessions for 4 months
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Innovations in Dementia Empowerment and Action (IDEA)
2018
N/A
~330

Find a Location

Who is running the clinical trial?

University of WashingtonLead Sponsor
1,738 Previous Clinical Trials
1,844,029 Total Patients Enrolled
National Institute on Aging (NIA)NIH
1,669 Previous Clinical Trials
28,004,792 Total Patients Enrolled
Karen Fredriksen-Goldsen, PhDPrincipal InvestigatorUniversity of Washington

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Innovations in Dementia Empowerment and Action
Karen Fredriksen Goldsen 2018. "Innovations in Dementia Empowerment and Action". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03550131.
~51 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top